Pelle L. Ishøy

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Pelle L. Ishøy, Filip K. Knop, Brian V. Broberg et al. · Diabetes Obesity and Metabolism · 2016 · 82 citations · Full text

No cognitive‐enhancing effect of <scp>GLP</scp>‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia

Pelle L. Ishøy, Birgitte Fagerlund, Brian V. Broberg et al. · Acta Psychiatrica Scandinavica · 2017 · 48 citations

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Bjørn H. Ebdrup, Filip K. Knop, Pelle L. Ishøy et al. · BMC Medicine · 2012 · 30 citations · Full text

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Pelle L. Ishøy, Filip K. Knop, Brian V. Broberg et al. · BMJ Open · 2014 · 24 citations · Full text

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Robert Eriksson, Brian V. Broberg, Pelle L. Ishøy et al. · Frontiers in Psychiatry · 2019 · 23 citations · Full text